Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 55.4%

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totaling 752,574 shares, a decline of 55.4% from the December 31st total of 1,689,232 shares. Based on an average daily volume of 461,342 shares, the days-to-cover ratio is currently 1.6 days. Currently, 2.3% of the company’s stock are sold short. Currently, 2.3% of the company’s stock are sold short. Based on an average daily volume of 461,342 shares, the days-to-cover ratio is currently 1.6 days.

VYNE Therapeutics Trading Down 0.9%

Shares of VYNE Therapeutics stock opened at $0.56 on Thursday. The company has a fifty day simple moving average of $0.50 and a 200-day simple moving average of $0.48. The stock has a market cap of $18.80 million, a price-to-earnings ratio of -0.72 and a beta of 1.95. VYNE Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.94.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 80.84%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. On average, analysts forecast that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on VYNE shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of VYNE Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, VYNE Therapeutics presently has a consensus rating of “Reduce” and an average price target of $4.50.

Institutional Investors Weigh In On VYNE Therapeutics

Several large investors have recently modified their holdings of VYNE. Baker BROS. Advisors LP acquired a new position in shares of VYNE Therapeutics in the 3rd quarter valued at $285,000. Kennedy Capital Management LLC purchased a new position in VYNE Therapeutics during the 2nd quarter worth $942,000. Shay Capital LLC acquired a new position in VYNE Therapeutics in the third quarter valued at $165,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after buying an additional 300,000 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of VYNE Therapeutics during the third quarter worth about $74,000. 83.78% of the stock is owned by institutional investors and hedge funds.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.